NASDAQ:OTICOtonomy Stock Price, Forecast & News

Otonomy's stock was trading at $2.62 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, OTIC stock has increased by 48.5% and is now trading at $3.89. View which stocks have been most impacted by Coronavirus.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Otonomy in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Otonomy.

Otonomy is scheduled to release its next quarterly earnings announcement on Thursday, August 6th 2020. View our earnings forecast for Otonomy.

Otonomy Inc (NASDAQ:OTIC) announced its quarterly earnings results on Thursday, May, 7th. The biopharmaceutical company reported ($0.38) earnings per share for the quarter, missing analysts' consensus estimates of ($0.36) by $0.02. The biopharmaceutical company had revenue of $0.16 million for the quarter. Otonomy had a negative return on equity of 98.90% and a negative net margin of 7,826.41%. View Otonomy's earnings history.

4 brokerages have issued twelve-month price targets for Otonomy's shares. Their forecasts range from $8.00 to $11.00. On average, they anticipate Otonomy's stock price to reach $9.00 in the next twelve months. This suggests a possible upside of 131.4% from the stock's current price. View analysts' price targets for Otonomy.

Media headlines about OTIC stock have been trending somewhat positive on Wednesday, according to InfoTrie Sentiment Analysis. The research group identifies positive and negative media coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Otonomy earned a coverage optimism score of 2.0 on InfoTrie's scale. They also assigned news stories about the biopharmaceutical company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an impact on the stock's share price in the immediate future. View the latest news about Otonomy.

Some companies that are related to Otonomy include Catalyst Pharmaceuticals (CPRX), Viking Therapeutics (VKTX), NextCure (NXTC), Clovis Oncology (CLVS), Urogen Pharma (URGN), Emisphere Technologies (EMIS), Mirum Pharmaceuticals (MIRM), Crinetics Pharmaceuticals (CRNX), BioSpecifics Technologies (BSTC), AC Immune (ACIU), Xenon Pharmaceuticals (XENE), Beyondspring (BYSI), Flexion Therapeutics (FLXN), Prothena (PRTA) and Fulcrum Therapeutics (FULC). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Otonomy investors own include Canaccord Genuity (), BMO Capital Markets (), Stifel Nicolaus (), Wunderlich (), Standpoint Research (), Duncan Williams (), Soleil Securities (), Sterne Agee CRT (), Robert W. Baird () and Wellington Shields ().

Otonomy trades on the NASDAQ under the ticker symbol "OTIC."

Shares of OTIC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of OTIC stock can currently be purchased for approximately $3.89.

Otonomy has a market capitalization of $120.08 million and generates $600,000.00 in revenue each year. The biopharmaceutical company earns $-44,670,000.00 in net income (profit) each year or ($1.45) on an earnings per share basis. Otonomy employs 49 workers across the globe.

The official website for Otonomy is www.otonomy.com.

Otonomy's mailing address is 4796 EXECUTIVE DRIVE, SAN DIEGO CA, 92121. The biopharmaceutical company can be reached via phone at 619-323-2200 or via email at [email protected]